Clinical Trial Update: Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP) [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic study of aprepitant in BEP treatment for testicular cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Testicular Cancer

Drugs mentioned

• Aprepitant (Emend) (aprepitant)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Nausea, Vomiting | Phase 4 | Status: WITHDRAWN